多参数磁共振成像靶向活检与系统性活检在检测前列腺癌楔形细胞和导管内癌方面的比较

IF 12.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Radiology Pub Date : 2024-07-01 DOI:10.1148/radiol.231948
Sangeet Ghai, Laurence Klotz, Gregory R Pond, Marlene Kebabdjian, Michelle R Downes, Eric C Belanger, Madeleine Moussa, Theodorus H van der Kwast
{"title":"多参数磁共振成像靶向活检与系统性活检在检测前列腺癌楔形细胞和导管内癌方面的比较","authors":"Sangeet Ghai, Laurence Klotz, Gregory R Pond, Marlene Kebabdjian, Michelle R Downes, Eric C Belanger, Madeleine Moussa, Theodorus H van der Kwast","doi":"10.1148/radiol.231948","DOIUrl":null,"url":null,"abstract":"<p><p>Background Intraductal carcinoma (IDC) and invasive cribriform (Cr) subtypes of prostate cancer (PCa) are an indication of aggressiveness, but the evidence regarding whether MRI can be used to detect Cr/IDC-pattern PCa is contradictory. Purpose To compare the detection of Cr/IDC-pattern PCa at multiparametric MRI (mpMRI)-targeted biopsy versus systematic biopsy in biopsy-naive men at risk for PCa. Materials and Methods This study was a secondary analysis of a prospective randomized controlled trial that recruited participants with a clinical suspicion of PCa between April 2017 and November 2019 at five centers. Participants were randomized 1:1 to either the MRI arm or the systematic biopsy arm. Targeted biopsy was performed in participants with a Prostate Imaging Reporting and Data System score of at least 3. MRI features were recorded, and biopsy slides and prostatectomy specimens were reviewed for the presence or absence of Cr/IDC histologic patterns. Comparison of Cr/IDC patterns was performed using generalized linear mixed modeling. Results A total of 453 participants were enrolled, with 226 in the systematic biopsy arm (median age, 65 years [IQR, 59-70 years]; 196 biopsies available for assessment) and 227 in the mpMRI-targeted biopsy arm (median age, 67 years [IQR, 60-72 years]; 132 biopsies available for assessment). Identification of Cr/IDC PCa was lower in the systematic biopsy arm compared with the mpMRI arm (31 of 196 biopsies [16%] vs 33 of 132 biopsies [25%]; <i>P</i> = .01). No evidence of a difference in mean cancer core length (CCL) (11.3 mm ± 4.4 vs 9.7 mm ± 4.5; <i>P</i> = .09), apparent diffusion coefficient (685 µm<sup>2</sup>/sec ± 178 vs 746 µm<sup>2</sup>/sec ± 245; <i>P</i> = .52), or dynamic contrast-enhanced positivity (27 [82%] vs 37 [90%]; <i>P</i> = .33) for clinically significant PCa (csPCa) was observed between participants with or without Cr/IDC disease in the MRI arm. Cr/IDC-positive histologic patterns overall had a higher mean CCL compared with Cr/IDC-negative csPCa (11.1 mm ± 4.4 vs 9.2 mm ± 4.1; <i>P</i> = .009). Conclusion MRI-targeted biopsy showed increased detection of Cr/IDC histologic patterns compared with systematic biopsy. Clinical trial registration no. NCT02936258 © RSNA, 2024 <i>Supplemental material is available for this article.</i> See also the editorial by Scialpi and Martorana in this issue.</p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Multiparametric MRI-targeted and Systematic Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate Cancer.\",\"authors\":\"Sangeet Ghai, Laurence Klotz, Gregory R Pond, Marlene Kebabdjian, Michelle R Downes, Eric C Belanger, Madeleine Moussa, Theodorus H van der Kwast\",\"doi\":\"10.1148/radiol.231948\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Background Intraductal carcinoma (IDC) and invasive cribriform (Cr) subtypes of prostate cancer (PCa) are an indication of aggressiveness, but the evidence regarding whether MRI can be used to detect Cr/IDC-pattern PCa is contradictory. Purpose To compare the detection of Cr/IDC-pattern PCa at multiparametric MRI (mpMRI)-targeted biopsy versus systematic biopsy in biopsy-naive men at risk for PCa. Materials and Methods This study was a secondary analysis of a prospective randomized controlled trial that recruited participants with a clinical suspicion of PCa between April 2017 and November 2019 at five centers. Participants were randomized 1:1 to either the MRI arm or the systematic biopsy arm. Targeted biopsy was performed in participants with a Prostate Imaging Reporting and Data System score of at least 3. MRI features were recorded, and biopsy slides and prostatectomy specimens were reviewed for the presence or absence of Cr/IDC histologic patterns. Comparison of Cr/IDC patterns was performed using generalized linear mixed modeling. Results A total of 453 participants were enrolled, with 226 in the systematic biopsy arm (median age, 65 years [IQR, 59-70 years]; 196 biopsies available for assessment) and 227 in the mpMRI-targeted biopsy arm (median age, 67 years [IQR, 60-72 years]; 132 biopsies available for assessment). Identification of Cr/IDC PCa was lower in the systematic biopsy arm compared with the mpMRI arm (31 of 196 biopsies [16%] vs 33 of 132 biopsies [25%]; <i>P</i> = .01). No evidence of a difference in mean cancer core length (CCL) (11.3 mm ± 4.4 vs 9.7 mm ± 4.5; <i>P</i> = .09), apparent diffusion coefficient (685 µm<sup>2</sup>/sec ± 178 vs 746 µm<sup>2</sup>/sec ± 245; <i>P</i> = .52), or dynamic contrast-enhanced positivity (27 [82%] vs 37 [90%]; <i>P</i> = .33) for clinically significant PCa (csPCa) was observed between participants with or without Cr/IDC disease in the MRI arm. Cr/IDC-positive histologic patterns overall had a higher mean CCL compared with Cr/IDC-negative csPCa (11.1 mm ± 4.4 vs 9.2 mm ± 4.1; <i>P</i> = .009). Conclusion MRI-targeted biopsy showed increased detection of Cr/IDC histologic patterns compared with systematic biopsy. Clinical trial registration no. NCT02936258 © RSNA, 2024 <i>Supplemental material is available for this article.</i> See also the editorial by Scialpi and Martorana in this issue.</p>\",\"PeriodicalId\":20896,\"journal\":{\"name\":\"Radiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.1000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1148/radiol.231948\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1148/radiol.231948","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

背景 前列腺癌(PCa)的导管内癌(IDC)和浸润性楔形细胞癌(Cr)亚型是侵袭性的一种表现,但有关磁共振成像是否可用于检测Cr/IDC型PCa的证据却相互矛盾。目的 比较多参数磁共振成像(mpMRI)靶向活检与系统性活检对PCa高危男性中Cr/IDC型PCa的检测效果。材料与方法 本研究是一项前瞻性随机对照试验的二次分析,该试验于2017年4月至2019年11月期间在五个中心招募了临床怀疑患有PCa的参与者。参与者按 1:1 随机分配到核磁共振成像组或系统活检组。对前列腺影像报告和数据系统评分至少为3分的参与者进行了靶向活检。记录了MRI特征,并对活检切片和前列腺切除术标本进行了审查,以确定是否存在Cr/IDC组织学模式。采用广义线性混合模型对Cr/IDC模式进行比较。结果 共有453名参与者参加,其中系统活检组226人(中位年龄65岁[IQR, 59-70岁];196份活检样本可供评估),mpMRI靶向活检组227人(中位年龄67岁[IQR, 60-72岁];132份活检样本可供评估)。系统活检组与 mpMRI 组相比,Cr/IDC PCa 的识别率较低(196 例活检中的 31 例 [16%] 与 132 例活检中的 33 例 [25%];P = .01)。在 MRI 组有或没有 Cr/IDC 病变的参与者之间,没有证据表明平均癌芯长度 (CCL) (11.3 mm ± 4.4 vs 9.7 mm ± 4.5; P = .09)、表观弥散系数 (685 µm2/sec ± 178 vs 746 µm2/sec ± 245; P = .52) 或动态对比增强阳性率 (27 [82%] vs 37 [90%]; P = .33) 有临床意义的 PCa (csPCa) 存在差异。与Cr/IDC阴性的csPCa相比,Cr/IDC阳性组织学形态的CCL平均值更高(11.1 mm ± 4.4 vs 9.2 mm ± 4.1;P = .009)。结论 与系统性活检相比,MRI靶向活检可提高Cr/IDC组织学模式的检出率。临床试验注册号NCT02936258 © RSNA, 2024 本文有补充材料。另请参阅 Scialpi 和 Martorana 在本期发表的社论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparison of Multiparametric MRI-targeted and Systematic Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate Cancer.

Background Intraductal carcinoma (IDC) and invasive cribriform (Cr) subtypes of prostate cancer (PCa) are an indication of aggressiveness, but the evidence regarding whether MRI can be used to detect Cr/IDC-pattern PCa is contradictory. Purpose To compare the detection of Cr/IDC-pattern PCa at multiparametric MRI (mpMRI)-targeted biopsy versus systematic biopsy in biopsy-naive men at risk for PCa. Materials and Methods This study was a secondary analysis of a prospective randomized controlled trial that recruited participants with a clinical suspicion of PCa between April 2017 and November 2019 at five centers. Participants were randomized 1:1 to either the MRI arm or the systematic biopsy arm. Targeted biopsy was performed in participants with a Prostate Imaging Reporting and Data System score of at least 3. MRI features were recorded, and biopsy slides and prostatectomy specimens were reviewed for the presence or absence of Cr/IDC histologic patterns. Comparison of Cr/IDC patterns was performed using generalized linear mixed modeling. Results A total of 453 participants were enrolled, with 226 in the systematic biopsy arm (median age, 65 years [IQR, 59-70 years]; 196 biopsies available for assessment) and 227 in the mpMRI-targeted biopsy arm (median age, 67 years [IQR, 60-72 years]; 132 biopsies available for assessment). Identification of Cr/IDC PCa was lower in the systematic biopsy arm compared with the mpMRI arm (31 of 196 biopsies [16%] vs 33 of 132 biopsies [25%]; P = .01). No evidence of a difference in mean cancer core length (CCL) (11.3 mm ± 4.4 vs 9.7 mm ± 4.5; P = .09), apparent diffusion coefficient (685 µm2/sec ± 178 vs 746 µm2/sec ± 245; P = .52), or dynamic contrast-enhanced positivity (27 [82%] vs 37 [90%]; P = .33) for clinically significant PCa (csPCa) was observed between participants with or without Cr/IDC disease in the MRI arm. Cr/IDC-positive histologic patterns overall had a higher mean CCL compared with Cr/IDC-negative csPCa (11.1 mm ± 4.4 vs 9.2 mm ± 4.1; P = .009). Conclusion MRI-targeted biopsy showed increased detection of Cr/IDC histologic patterns compared with systematic biopsy. Clinical trial registration no. NCT02936258 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Scialpi and Martorana in this issue.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiology
Radiology 医学-核医学
CiteScore
35.20
自引率
3.00%
发文量
596
审稿时长
3.6 months
期刊介绍: Published regularly since 1923 by the Radiological Society of North America (RSNA), Radiology has long been recognized as the authoritative reference for the most current, clinically relevant and highest quality research in the field of radiology. Each month the journal publishes approximately 240 pages of peer-reviewed original research, authoritative reviews, well-balanced commentary on significant articles, and expert opinion on new techniques and technologies. Radiology publishes cutting edge and impactful imaging research articles in radiology and medical imaging in order to help improve human health.
期刊最新文献
Amplifying Research in Radiology: The Podcast Effect. Amplifying Research: The Potential for Podcasts to Boost Radiology Journal Article Exposure. Automated Interstitial Lung Abnormality Probability Prediction at CT: A Stepwise Machine Learning Approach in the Boston Lung Cancer Study. Biomarkers for Personalized Neoadjuvant Therapy in Triple-Negative Breast Cancer: Moving Forward. Calcified Osteosarcoma Lung Metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1